Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
4.820
0.00 (0.00%)
Dec 3, 2024, 12:02 PM EST - Market open
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 5 or -33.33% compared to the previous year.
Employees
10
Change (1Y)
-5
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,479,564
Market Cap
287.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
uniQure | 480 |
Lexicon Pharmaceuticals | 285 |
Vanda Pharmaceuticals | 203 |
Perspective Therapeutics | 119 |
Aclaris Therapeutics | 91 |
Atai Life Sciences | 83 |
Atea Pharmaceuticals | 75 |
Ocugen | 65 |
ALDX News
- 1 day ago - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference - Business Wire
- 15 days ago - Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement - Business Wire
- 19 days ago - Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference - Business Wire
- 19 days ago - Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects - Seeking Alpha
- 4 weeks ago - Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - Business Wire
- 2 months ago - Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Business Wire
- 3 months ago - Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 3 months ago - Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership - Seeking Alpha